Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Renata PLC · Tablet
/ Piece
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Lurasidone is indicated for:
Schizophrenia
Depressive episodes associated with Bipolar disorder
The mechanism of action of Lurasidone in the treatment of schizophrenia and bipolar depression is unknown. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type-2 (5HT2A) receptor antagonism.
Lurasidone should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of LurasidoneSchizophrenia: The recommended starting dose of Lurasidone is 40 mg once daily. Initial dose titration is not required. The maximum recommended dose is 160 mg per day.Depressive Episodes Associated with Bipolar I Disorder: The recommended starting dose of Lurasidone is 20 mg given once daily as monotherapy or as adjunctive therapy with lithium or valproate. Initial dose titration is not required. The maximum recommended dose, as monotherapy or as adjunctive therapy with lithium or valproate, is 120 mg per day.Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Lurasidone should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, etc.)
Commonly observed adverse reactions are-somnolence, akathisia, extrapyramidal symptoms, and nausea etc.
Pregnancy Category B. Nursing mothers: Lurasidone is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Lurasidone, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
It can cause increased mortality in elderly patients with dementia-related psychosis, increase suicidal thoughts and behaviors in adolescents and young adults.
Atypical neuroleptic drugs
Store at temperature not exceeding 30°C in a dry place. Protect from light.